The Tradeoffs Of Continuous Processing

Why It Matters

Adopting continuous harvest to Protein A can slash manufacturing costs for blockbuster biologics, yet the high development overhead makes it unsuitable for most early‑phase programs, forcing companies to strategically time its implementation.

Key Takeaways

• Continuous harvest directly to Protein A hinges on downstream capacity.
• Residence time stability in surge tanks critical for product quality.
• Early validation of stability design space reduces future regulatory deviations.
• High development effort may outweigh benefits for early‑phase programs.
• Continuous processing best suited for blockbuster antibodies with large demand.

Summary

The panel addressed a recurring audience query about whether continuous processing—specifically harvesting antibody‑producing bioreactors and loading directly onto Protein A chromatography—can be implemented under GMP conditions. The discussion framed the issue as a balance between upstream output and downstream handling, asking participants to consider the practical limits of a fully continuous line.

Speakers highlighted two technical pillars: downstream capacity, including resin utilization and the ability to keep the line moving without bottlenecks, and residence‑time stability in surge tanks, which must be defined and validated early to avoid quality excursions. Establishing a robust design space for product hold‑time and stability was presented as a way to mitigate future regulatory deviations and reduce overall development cost.

Raj emphasized staggered production and end‑to‑end flow, while Eric underscored the importance of residence‑time profiles. Mark warned that the added complexity of continuous Protein A may not pay off until commercial scale, noting that most Phase 1 programs never reach Phase 3. Doug added that only high‑volume, blockbuster antibodies—where demand justifies the investment—are clear candidates for continuous operation.

The consensus suggests that biopharma firms should reserve continuous harvest‑to‑Protein A for late‑stage, high‑demand projects, and focus on rapid, platform‑based Phase 1 launches elsewhere. Early validation of stability parameters can smooth regulatory pathways, but the upfront development effort may outweigh benefits for most early‑stage molecules.

Original Description

Continuous bioprocessing has real benefits from a productivity standpoint, but it’s not inherently the best model for every process, especially in early stage development. In this segment from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration,” our panelists discuss how and when to approach continuous manufacturing, which can be great for commercial stage processes, but may not be worth the time or resources in Phase 1.